# Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects

> **NCT00779766** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 6081 (actual)

## Conditions studied

- Infections, Papillomavirus

## Interventions

- **BIOLOGICAL:** HPV GSK 580299 vaccine
- **BIOLOGICAL:** Placebo control

## Key facts

- **NCT ID:** NCT00779766
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10-22
- **Primary completion:** 2011-09-06
- **Final completion:** 2016-02-28
- **Target enrollment:** 6081 (ACTUAL)
- **Last updated:** 2019-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00779766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00779766, "Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00779766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*